Experimental Treatments

Overview

Current treatments of ANCA-associated vasculitis (AAV) can lead to remission but cannot cure the condition. Researchers are trying to develop therapies that achieve faster remission and keep symptoms under control longer, as well as trying to find a cure. Learn more about some of the therapies being developed for AAV.

Benlysta

Benlysta (belimumab) is an approved therapy for lupus that is also being investigated to see if it can prevent flares or relapses in people with ANCA vasculitis. Benlysta is an antibody-based drug that blocks a chemical messenger in the blood known as BLyS or BAFF. As of 2019, the therapy was in Phase 3 testing for ANCA vasculitis.

Learn more

Lixudebart

Lixudebart is an experimental infusion therapy being developed by Alentis Therapeutics to manage serious kidney disease that arises as a complication of AAV.

Learn more